Details for Patent: 12,551,491

« Back to Dashboard

Which drugs does patent 12,551,491 protect, and when does it expire?

Patent 12,551,491 protects ZUNVEYL and is included in one NDA.

Summary for Patent: 12,551,491

Title:	Dosage regimens for benzgalantamine
Abstract:	A method of effectively reducing the pharmaceutical load of galantamine relative to oral administration of galantamine or a method of effectively administering galantamine in a subject in need of galantamine therapy for the treatment of mild to moderate dementia of the Alzheimer's type, the methods including orally administering a dosage form of benzgalantamine gluconate according to the following dosage regime: administering a starting dosage of 5 mg benzgalantamine gluconate, twice daily, for a minimum of four weeks.
Inventor(s):	Michael McFadden, Denis G. Kay
Assignee:	Alpha Cognition Inc
Application Number:	US19/278,636
Patent Claim Types: see list of patent claims	Use; Dosage form;

Drugs Protected by US Patent 12,551,491

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Alpha Cognition	ZUNVEYL	benzgalantamine gluconate	TABLET, DELAYED RELEASE;ORAL	218549-001	Jul 26, 2024		RX	Yes	Yes						TREATMENT OF MILD TO MODERATE DEMENTIA OF THE ALZHEIMER'S TYPE
Alpha Cognition	ZUNVEYL	benzgalantamine gluconate	TABLET, DELAYED RELEASE;ORAL	218549-002	Jul 26, 2024		RX	Yes	No						TREATMENT OF MILD TO MODERATE DEMENTIA OF THE ALZHEIMER'S TYPE
Alpha Cognition	ZUNVEYL	benzgalantamine gluconate	TABLET, DELAYED RELEASE;ORAL	218549-003	Jul 26, 2024		RX	Yes	No						TREATMENT OF MILD TO MODERATE DEMENTIA OF THE ALZHEIMER'S TYPE